Recent Updates
Recently added Catalysts

Danaher Corporation

DHRFDA catalysts, PDUFA dates & pipeline intelligence
$227.56
▼ -1.02 · -0.45%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full DHR financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $160.9352W HIGH $242.80
Volume
4.10 M
Value Traded
934.40 M
Short % Float
1.31%
Days to Cover
1.8
+3.88%Week
-11.32%1 Month
-17.6%3 Month
-22.78%6 Month
-24.07%5 Year
+28,772.96%All Time

Cash Data

Unlock DHR cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
160.10 B
EPS (TTM)
5.20
P/E Ratio
33.24
Ent. Value
135.73 B
Total Shares
703.06 M
Float Shares
640.36 M
Insiders
8.98%
Institutions
86.19%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every DHR catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

DHR Catalyst Timeline

Dated clinical, regulatory and corporate events for Danaher Corporation

Unlock the full DHR catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How DHR actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all DHR historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Danaher Corporation is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every DHR program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every DHR trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock DHR insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Milosevich Gregory MOfficer (Executive Vice President)Sell -2,100 22,367 held$230.62 11/09/2026
Unlock the full DHR insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
RTW INVESTMENTS, LP 0.5 % (25 %) 50.96 M 230.00 K
Unlock every fund holding DHR
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in DHR
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see DHR ownership
Insider and institutional ownership, quarter by quarter.

DHR Short Interest

Shares sold short, counted twice a month.

1.31%
Short % of Float
of tradable shares sold short
8.4M
Shares Sold Short
+2.9% vs prior count
1.8 Low
Days to Cover
trading days of normal volume to buy every short share back
4.8M
Avg Daily Volume
the average used for days to cover
Unlock DHR short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock DHR option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live DHR option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock DHR options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How DHR ranks across every disease it competes in

Competitive Position is a premium feature
See how DHR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

DHR News

DHR
Nov 2, 2026
DHRConferences/Events

Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences

Danaher Corporation announced that CEO Julie Sawyer Montgomery will present at the UBS Global Healthcare Conference on November 9, 2026, and the Jefferies Global Healthcare Conference on November 17, 2026. Both presentations will be available via webcast. Danaher continues to lead in life sciences and biotechnology innovation.

Read more →
DHR
Oct 21, 2026
DHRGeneral

Danaher Reports Third Quarter 2026 Results

Danaher Corporation reported strong third quarter results for 2026, with net earnings of $1.2 billion, a 34.5% increase from the previous year. Revenues reached $6.6 billion, reflecting an 8.5% year-over-year growth. The company also raised its full-year adjusted diluted net earnings guidance, indicating positive financial momentum.

Read more →
DHR
Oct 14, 2026
DHRGeneral

Danaher Collaborates with NVIDIA to Advance Autonomous Science

Danaher Corporation has announced a collaboration with NVIDIA to enhance autonomous science by integrating AI technologies with scientific instruments. This partnership aims to streamline laboratory workflows and accelerate scientific discovery, allowing researchers to transition from predictions to experimental evidence more efficiently. The initiative reflects Danaher's commitment to innovation in AI-enabled science.

Read more →
DHR
Oct 12, 2026
DHRGeneral

Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors

Danaher Corporation has appointed Daniel L. Comas and Robert Hershberg, M.D., Ph.D., to its Board of Directors, expanding the Board from 11 to 13 members. Comas brings extensive experience from his tenure at Danaher, while Hershberg adds significant scientific and biopharmaceutical expertise. Alan G. Spoon will retire from the Board at the 2027 Annual Meeting.

Read more →
DHR
Oct 7, 2026
DHRGeneral

Danaher Accelerates Life Sciences Research with New AI-powered Autonomous Lab

Danaher Corporation has announced the launch of its first AI-powered autonomous lab, aimed at accelerating the development of custom antibodies and molecular tools. Set to operate at scale in early 2027, the lab will utilize AI and robotics to enhance research efficiency, enabling up to eight times faster discovery of affinity reagents. This initiative is part of a broader strategy to integrate smart instruments and workflows in scientific research.

Read more →
DHR
Oct 1, 2026
DHRGeneral

Julie Sawyer Montgomery Assumes Role as Danaher President and Chief Executive Officer

Julie Sawyer Montgomery has officially taken on the roles of President and CEO of Danaher Corporation, effective October 1, 2026. She has been with the company since 2017, holding various leadership positions that have contributed to its growth and innovation. Rainer Blair will assist in the transition as a senior advisor until March 31, 2027.

Read more →
DHR
Sep 22, 2026
DHRConferences/Events

Danaher Schedules Third Quarter 2026 Earnings Conference Call

Danaher Corporation has scheduled its third quarter 2026 earnings conference call for October 21, 2026. The call will cover financial performance and future expectations, lasting approximately one hour. Investors can access the call via a dedicated phone line or through a webcast on Danaher's website, with a replay available afterward.

Read more →
DHR
Sep 15, 2026
DHRGeneral

Danaher Announces Quarterly Dividend

Danaher Corporation has declared a quarterly cash dividend of $0.40 per share, set to be paid on October 30, 2026, to shareholders on record as of September 30, 2026. This announcement highlights Danaher's ongoing commitment to returning value to its shareholders while maintaining a focus on innovation in life sciences and diagnostics.

Read more →
DHR
Aug 3, 2026
DHRGeneral

Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer

Danaher Corporation has appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026, succeeding Rainer Blair, who will retire. Montgomery has been instrumental in growing Danaher's Diagnostics platform significantly since joining in 2017. Her leadership is expected to drive further innovation and growth within the company.

Read more →
DHR
Jul 21, 2026
DHRGeneral
▼ -11%on this news

Danaher Reports Second Quarter 2026 Results

Danaher Corporation reported a strong second quarter for 2026, with net earnings rising 60% year-over-year to $870 million. Revenue also increased by 5.5% to $6.3 billion, driven by robust performance in the Life Sciences segment. The company has raised its full-year earnings guidance, reflecting optimism about continued growth despite some challenges in bioprocessing revenue.

Read more →
DHR
Jun 29, 2026
DHRGeneral

Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa

The Danaher Foundation has pledged $1 million to support urgent Ebola outbreak relief efforts in Central Africa, specifically in the Democratic Republic of Congo and Uganda. The funding will be allocated to Save the Children, the International Rescue Committee, and the World Food Program to address critical needs such as infection prevention and emergency food assistance. This support aims to enhance the response to the ongoing outbreak, which has already confirmed over 1,000 cases.

Read more →
DHR
Jun 22, 2026
DHRConferences/Events

Danaher Schedules Second Quarter 2026 Earnings Conference Call

Danaher Corporation has announced its quarterly earnings conference call for Q2 2026, scheduled for July 21, 2026. The call will cover the company's financial performance and future expectations. Interested parties can access the call via a dedicated phone line or through a webcast on Danaher's website. A replay will be available after the call.

Read more →
DHR
May 6, 2026
DHRConferences/Events

Danaher to Present at Bank of America Securities Healthcare Conference

Danaher Corporation's CEO, Rainer M. Blair, will present at the Bank of America Securities Healthcare Conference on May 13, 2026. The event will take place in Las Vegas and will be available via webcast. Danaher is recognized for its innovative contributions to life sciences and diagnostics, aiming to enhance human health.

Read more →
DHR
Apr 22, 2026
DHRGeneral
▼ -5.4%on this news

Danaher Announces Pricing of Euro-Denominated Senior Notes Offering

Danaher Corporation has announced the pricing of a euro-denominated senior notes offering totaling €2.98 billion. The offering includes various notes with different maturities and interest rates, aimed at funding the acquisition of Masimo Corporation. The closing of the offering is anticipated on April 29, 2026, pending customary conditions.

Read more →
DHR
Apr 21, 2026
DHRGeneral

Danaher Reports First Quarter 2026 Results

Danaher Corporation reported strong first quarter results for 2026, with net earnings reaching $1.0 billion and a 9.5% increase in adjusted diluted earnings per share. Revenues rose 3.5% year-over-year, driven by growth in Bioprocessing and Life Sciences. The company also announced plans to acquire Masimo Corporation, which is expected to enhance its capabilities in patient monitoring. However, a lighter-than-expected respiratory season at Cepheid posed challenges.

Read more →
DHR
Apr 13, 2026
DHRFDA Updates

Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes

Beckman Coulter Diagnostics has received CE mark approval for its Access MeMed BV assay, which allows for rapid differentiation between bacterial and viral infections in about 20 minutes. This assay can significantly reduce healthcare costs in Europe by minimizing unnecessary admissions and testing. By leveraging existing laboratory infrastructure, it aims to enhance clinical decision-making and support antimicrobial stewardship.

Read more →
DHR
Mar 20, 2026
DHRConferences/Events

Danaher Schedules First Quarter 2026 Earnings Conference Call

Danaher Corporation has scheduled its first quarter 2026 earnings conference call for April 21, 2026, at 8:00 a.m. ET. The call will cover the company's financial performance and future expectations. A replay will be available after the call, along with related materials on Danaher's website.

Read more →
DHR
Feb 24, 2026
DHRConferences/Events

Danaher to Present at TD Cowen Health Care Conference

Danaher Corporation announced that CEO Rainer M. Blair will present at the TD Cowen Healthcare Conference on March 3, 2025, at 1:50 p.m. ET. The event will be webcast live and accessible via Danaher's website. The company emphasizes its commitment to innovation in life sciences and diagnostics.

Read more →

About Danaher Corporation

Washington, DC 60,000 employees danaher.com
Headquarters2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC, 20037-1701
BIOPHARMAWATCH ELITE
Trade the next DHR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime